Clinical Trial Update: Study to Investigate the Seropersistence of TBE Virus Antibodies Approx. 3 Years After a Booster Vaccination With FSME-IMMUN 0.25 mL JUNIOR in Children

View source ↗

Summary

The study evaluated the persistence of TBE virus antibodies about three years after a booster dose of FSME-Immun Junior in children. The trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tick-borne Encephalitis

Drugs mentioned

• FSME-Immun Junior (Tick-borne encephalitis vaccine, inactivated)

Snippet

Sponsor: Pfizer | Conditions: Encephalitis, Tick-borne | Status: COMPLETED